Orbimed Advisors - ARCUTIS BIOTHERAPEUTICS INC ownership

ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$10,165,883
-44.3%
1,914,4790.0%0.22%
-34.7%
Q2 2023$18,244,985
-13.4%
1,914,4790.0%0.33%
-19.9%
Q1 2023$21,059,269
-42.2%
1,914,479
-22.2%
0.41%
-40.7%
Q4 2022$36,409,598
-32.0%
2,460,108
-12.1%
0.70%
-29.8%
Q3 2022$53,508,000
-47.5%
2,800,000
-41.4%
0.99%
-46.2%
Q2 2022$101,897,000
-12.9%
4,781,646
-21.3%
1.85%
-2.7%
Q1 2022$116,982,000
-7.1%
6,073,8500.0%1.90%
+17.2%
Q4 2021$125,972,000
-13.2%
6,073,8500.0%1.62%
+1.5%
Q3 2021$145,104,000
-12.5%
6,073,8500.0%1.60%
-4.9%
Q2 2021$165,755,000
-5.7%
6,073,8500.0%1.68%
+2.1%
Q1 2021$175,716,000
+2.8%
6,073,8500.0%1.64%
+9.9%
Q4 2020$170,857,000
+24.8%
6,073,850
+30.0%
1.50%
-13.1%
Q3 2020$136,944,000
-3.1%
4,673,8500.0%1.72%
-13.5%
Q2 2020$141,337,000
+1.5%
4,673,8500.0%1.99%
-15.0%
Q1 2020$139,281,0004,673,8502.34%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,684,232$165,956,00012.78%
Bain Capital Life Sciences Investors, LLC 3,000,000$57,330,0006.84%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,874,0003.97%
Logos Global Management LP 1,525,000$29,143,0003.58%
1492 Capital Management LLC 178,320$3,408,0002.45%
Cormorant Asset Management, LP 1,000,000$19,110,0001.34%
MPM BioImpact LLC 257,185$4,915,0001.16%
Orbimed Advisors 2,800,000$53,508,0000.99%
SECTORAL ASSET MANAGEMENT INC 220,985$4,223,0000.83%
Rubric Capital Management LP 472,047$9,021,0000.45%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders